World‘s best in class pKa prediction tool
pKa important factor in research screening cascade of molecules
What needs to be completed for collaboration?
Importance of pKa in Drug Discovery
ADMET Predictor® as a de novo drug design environment
Physiologically-Based Pharmacokinetic (PBPK) Modeling is a Tool/Component of Model-Informed Drug Development (MIDD)
The PKB model structure depends on the problem, knowledge of the biokinetic mechanism, and availability of suitable data
Discuss advances in mechanistic models to simulate in vitro and in vivobehavior of long acting injectables.
It is challenging to establish a standard approach for moving from preclinical to clinical phases of development. Many hurdles exist during formulation selection and for extrapolation of doses from animals to humans; what may have worked well for one drug candidate may not be appropriate for others. This presentation will provide a general framework/strategy to follow when moving from preclinical to clinical studies (FIH) based on risk identification and mitigation focusing on the application of mechanistic modeling and simulation (PBPK).
Number of different processes contribute to net drug absorption
Generic drug development for locally acting drug products is a fast-growing field of interest
PBPK/PBBM model development can be initiated at any stage of product development
The role of biopharmaceutics risk assessment
Our solutions inform the entire drug development process
Mechanistic High-Throughput PK
Do you think modeling and simulation might help?
Many drug molecules exhibit tautomerism
Computer based de novo drug design background
PBPK model description